Moderna and Merck shares retreated after trial results for their personalized melanoma vaccine showed a 42% lower recurrence risk, falling short of investor expectations based on earlier, stronger data. The results represent a key test for Moderna's mRNA cancer platform and Merck's effort to expand the use of its blockbuster drug, Keytruda.
Shares of Moderna Inc. and Merck & Co. declined on Thursday following the release of new clinical data regarding their personalized cancer vaccine. The market reaction indicates a gap between the actual trial findings and the high growth expectations investors had set for the collaboration.
Vaccine Trial Results and Investor Expectations
The final-stage trial results showed that the mRNA-based vaccine, used alongside Merck’s drug Keytruda, reduced the risk of cancer recurrence by 42%. Additionally, the treatment showed a 38% reduction in the risk of the cancer spreading to distant parts of the body. While these figures indicate that the treatment is working, they did not meet the higher expectations set by an earlier, smaller study. In that previous report, the recurrence risk was reduced by 49%, and the risk of distant spread was lowered by 59%.
Investors had been banking on these new results to confirm that the earlier high performance would be maintained in a larger group of patients. Because the new data showed slightly weaker results than the previous, smaller trial, the stock price reaction was negative. Moderna shares saw a steeper decline, reflecting its reliance on proving that its mRNA technology can succeed beyond COVID-19 vaccines.
Strategic Importance of the mRNA Platform
For Moderna, the melanoma trial is more than just one project; it is a test of its future. The company is attempting to prove that its mRNA technology can be a standard way to treat various types of tumors, including lung and bladder cancer. If the technology fails to show strong, consistent results in large trials, the company faces pressure to demonstrate how it will generate future revenue.
For Merck, the goal is to maintain the long-term dominance of Keytruda, which is one of the most successful cancer drugs in history. By pairing it with a personalized vaccine, the company hopes to create a new way to keep cancer from returning. However, the current data suggests that the results are not the immediate, massive breakthrough that investors had hoped would justify current valuations.
Financial Context and Outlook
Investors often price companies based on the expectation of successful, high-impact clinical results. When results are positive but do not hit the specific, ambitious levels expected, stocks can fall as investors reset their growth forecasts. This appears to be the case here, as the market recalibrates the potential for immediate commercial success.
Looking ahead, investors will be monitoring upcoming data from trials in other areas of cancer treatment. The long-term commercial success of this partnership depends on whether the companies can prove that their mRNA vaccine consistently works across a wider spectrum of cancer types. The next update from these ongoing trials will be a key factor for the stock performance of both companies.